Table 2.
Ivermectin intake during the 2017 CDTI by sex, age group, and village.
| Makoko | Wela |
p-Value (Makoko vs. Wela) |
Total (Makoko and Wela) |
p-Value | ||
|---|---|---|---|---|---|---|
| Sex-specific ivermectin coverage, n (%) | Male | 90/140 (64.3%) | 152/305 (49.8%) | 0.003 | 242/445 (54.3%) | Male vs. female, p = 0.18 |
| Female | 95/147 (64.6%) | 158/294 (53.7%) | 0.014 | 253/441 (57.4%) | ||
| Total | 185/287 (64.5%) | 310/599 (51.8%) | 0.0002 | 495/886 (55.9%) | ||
| Age-specific ivermectin coverage, n (%) | 5–10 years | 37/65 (56.9%) | 72/126 (57.1%) | 0.4880 | 109/191 (57.1%) | 0.0001a |
| 11–20 years | 46/55 (83.6%) | 75/102 (73.5%) | 0.0749 | 121/157 (77.1%) | ||
| 21–30 years | 29/33 (87.9%) | 48/77 (62.3%) | 0.0040 | 77/110 (70.0%) | ||
| 31–40 years | 28/32 (87.5%) | 51/75 (68.0%) | 0.0178 | 79/107 (73.8%) | ||
| >40 years | 45/53 (84.9%) | 64/100 (64.0%) | 0.0030 | 109/153 (71.2%) | ||
| Total | 185/238 (77.7%) | 310/480 (64.6%) | 0.0002 | 495/718 (68.9%) | ||
CDTI, community-directed treatment with ivermectin.
a
Chi-square test, corresponding p-value across age groups.